BioCentury
ARTICLE | Emerging Company Profile

Aluda: targeting the fundamentals

Aluda begins to unveil pipeline, starting with first-in-class anti-VIM program for fibrosis

January 25, 2020 1:48 AM UTC
Updated on Jan 30, 2020 at 7:59 PM UTC

Five years after its launch, Aluda is pulling back the curtain on its pipeline, leading with a first-in-class anti-VIM therapy for fibrotic indications.

CEO Ruihuan Chen co-founded Aluda Pharmaceuticals Inc. in 2015 after 13 years at Genentech Inc. with the goal of discovering novel compounds that target fundamental processes associated with pathogenesis. Chen also co-founded Natrogen Therapeutics Intl. Inc., which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired...



Access The Full Article

BCIQ Target Profiles

Vimentin (VIM)